cbdMD Inc. Common Stock (YCBD)

FairStock Score: 46/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At the close on 2026-10-13, cbdMD traded at $0.35 with a $4.0 million market value, so the stock is tiny and the market is skeptical. The company sells CBD oils, gummies, topicals and pet products, but the filed record shows no durable profit: FY2023 revenue was $25.1 million with a $22.9 million net loss; FY2024 revenue was $19.9 million with a $3.7 million loss; FY2025 revenue was $19.2 million with a $2.0 million loss. In fiscal Q3 2026, the quarter ended 2026-06-30, revenue was $5.6 million and net loss was $1.1 million, versus fiscal Q3 2025 revenue of $4.6 million and net loss of $895,272. So sales have ticked up, but losses remain and the latest quarter was worse year over year. FairStock's calculations show why this is not a classic Graham bargain: trailing free cash flow is -$2.4 million, FCF yield is -60.6%, ROE is -40.33%, ROCE is -15.75%, Piotroski is 1/9, and Altman Z is -18.32. The P/B of 0.46 and Graham Number of $1.96 look cheap, but Graham wanted earnings and balance-sheet strength, not just a low asset multiple. The P/E of 1.54 at the 2026-10-13 close is distorted by a positive FairStock EPS calculation while the filed statements show losses. cbdMD operates in a commoditized, regulated CBD market with only 42 employees; I see little moat. The Lynch category is none because it lost money in each of the last four years. This is a speculative turnaround, not a safe value investment.

In plain English: cbdMD makes CBD oils, gummies, topicals and pet products. The business has been losing money and burning cash in recent years, even though sales have grown a little lately. At $0.35 a share, the market values it very low compared with its book value, but the losses make it hard to call the price a safe bargain.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q3 2026 10-Q (period ended 2026-06-30) · fiscal Q2 2026 10-Q (period ended 2026-03-31) · fiscal Q1 2026 10-Q (period ended 2025-12-31) · fiscal Q3 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-09-30) · FY2024 10-K (period ended 2024-09-30) · FY2023 10-K (period ended 2023-09-30)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer